Aims/hypothesis Adenosine is an important regulator of metabolism; however, the role of the A 1 receptor during ageing and obesity is unclear. The aim of this study was to investigate the effects of A 1 signalling in modulating metabolic function during ageing. Methods Age-matched young and aged A 1 (also known as Adora1)-knockout (A 1
) mice were used. Metabolic regulation was evaluated by body composition, and glucose and insulin tolerance tests. Isolated islets and islet arterioles were used to detect islet endocrine and vascular function. Oxidative stress and inflammation status were measured in metabolic organs and systemically. Results Advanced age was associated with both reduced glucose clearance and insulin sensitivity, as well as increased Electronic supplementary material The online version of this article (doi:10.1007/s00125-015-3570-3) contains peer-reviewed but unedited supplementary material, which is available to authorised users.
Introduction
Type 2 diabetes is characterised by beta cell dysfunction and insulin resistance [1] [2] [3] leading to endothelial dysfunction with devastating long-term vascular impairment manifested as numerous complications [4, 5] . The incidence of type 2 diabetes increases with age and obesity, both of which are associated with oxidative stress and chronic inflammation. Mechanistic insights into the pathogenesis of type 2 diabetes and novel therapeutic approaches are urgently needed. Several clinical and epidemiological studies have demonstrated that coffee consumption, mainly caffeine itself, is associated with a reduced risk of developing type 2 diabetes [6] [7] [8] . Caffeine inhibits the receptor-mediated actions of adenosine [9] , which exerts biological effects via four types of receptors (A 1 , A 2A , A 2B and A 3 ) [10] . Adenosine is an important regulator of metabolism; it modulates visceral adipose tissue (VAT) function through A 1 receptor-mediated actions in decreasing lipolysis and increasing lipogenesis [11, 12] . Studies utilising gene-modified mice have also suggested that the A 1 receptor interacts with insulin and glucagon signalling [13, 14] or secretion [15] . Adenosine was demonstrated to mediate metabolically induced vasodilation in several tissues [16, 17] , and we have previously shown that A 1 receptor activation modulates in vivo islet blood flow in response to glucose [18] .
These results, all obtained in younger animals, indicate that adenosine, via A 1 signalling, could affect glucose homeostasis in multiple ways. However, the role of the A 1 receptor in agerelated metabolic disorders, which is an independent risk factor of type 2 diabetes [19] [20] [21] [22] [23] , has not been clearly studied. We hypothesised that abrogation of A 1 receptor signalling attenuates metabolic dysfunction associated with ageing and obesity, by modulating islet function, oxidative stress and inflammatory responses. Indeed, our findings demonstrate this and may have therapeutic implications.
Methods
This study was approved by the Institutional Animal Care and Use Committee (IACUC) at Georgetown University, and by equivalent IACUCs in Uppsala and Stockholm, and was performed according to the National Institutes of Health guidelines for the conduct of experiments in animals.
Animals Experiments were conducted on adenosine A 1 receptor gene (also known as Adora1)-deleted (A 1 −/− ) and wild-type mice (A 1 +/+ ) from heterozygous breeding pairs. The strain was developed by Johansson and co-workers [24] and backcrossed by the Jackson Laboratory (Bar Harbor, ME, USA) to a C57BL/6J background. Both sexes were used, with equal distribution for young (3-5 months) and aged (14-16 months) mice. Mice were housed in temperaturecontrolled rooms with 12 h light/dark cycles and received a standard rodent chow (4% fat, R36, Lactamin AB, Kimstad, Sweden) and tap water ad libitum.
Food intake and body composition analysis Food intake was assessed (96 h period) and dual-emission x-ray absorptiometry (DEXA) studies were performed using a Lunar PIXImus densitometer (GE Medical-Lunar, Madison, WI, USA) in isoflurane-anaesthetised (Forene; Abbott Scandinavia AB, Solna, Sweden) animals to determine fat and lean masses, as previously described [25] .
Glucose and insulin tolerance test Intraperitoneal glucose (IPGTT) and insulin tolerance tests (IPITT) were performed, and the acute effects of pharmacological inhibition of the A 1 receptor with 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), a potent and selective antagonist for the A 1 receptor (0.2 mg/kg body weight; Sigma-Aldrich; St Louis, MO, USA) or saline (154 mmol/l NaCl; placebo) were investigated. See Electronic Supplementary Material (ESM) Methods for further details.
Pancreatic islet arterioles: vascular reactivity studies Single islets with attached arterioles were dissected and perfused, as previously described [26] . Arteriolar responses to angiotensin II (ANG II; 10 −6 to 10 −12 mol/l; Sigma-Aldrich) alone, or together with apocynin (10 −4 mol/l; Sigma-Aldrich) were investigated during high (16.7 mmol/l) and low glucose (2.8 mmol/l). Dose-responses to adenosine (10 −4 to 10 −11 mol/l; Sigma-Aldrich) were also investigated.
See ESM Methods for further details.
Pancreatic islets: insulin release and contents Mouse pancreatic islets were isolated through collagenase digestion and cultured in groups of 150 islets for 3 days. Insulin release was measured in groups of ten islets from each animal after incubation with low (1.67 mmol/l) and high (16.7 mmol/l) glucose. Insulin content in the incubation media and homogenates were determined using a mouse insulin ELISA kit (Mercodia, Uppsala, Sweden) [27] .
Lucigenin-dependent chemiluminescence of superoxide production NADPH oxidase-mediated superoxide (O 2 − ) formation was detected by lucigenin-dependent chemiluminescence assay [28] . Pancreas, liver and VAT were separately homogenised and used for subsequent activity measurement. See ESM Methods for further details. 
Plasma analysis

Results
Animal characteristics Body weight was similar in young mice between genotypes. However, aged A 1 −/− had slightly lower body weight than A 1 +/+ mice (Fig. 1a) , despite similar daily food intake (Fig. 1b) . DEXA analysis revealed an ageing-related lean mass decrease (Fig. 1c, d ) and abdominal fat increase (Fig. 1e, f 
Glucose and insulin tolerance tests To investigate the role of A 1 receptors in modulating the metabolic phenotype during ageing, we performed glucose and insulin tolerance tests in young and aged mice. There was no difference in basal blood glucose levels or in glucose tolerance between genotypes in young mice (Fig. 2a) . However, in aged mice, fasting blood glucose was somewhat higher in
±0.2 vs 5.9±0.2 mmol/l, p<0.05), and IPGTT revealed significantly better glucose homeostasis in aged A 1 −/− mice ( Fig. 2b, c) . The glucose lowering effect of insulin was similar between genotypes at a young age (Fig. 2d) . Ageing was associated with reduced insulin sensitivity ( Fig. 2e ) and increased AUC (Fig. 2f ) in A 1
To validate the effect of A 1 receptor inhibition on glucose tolerance and insulin sensitivity, paired crossover measurements were conducted in aged mice. DPCPX significantly improved both glucose ( Metabolic hormones in plasma Advanced age was associated with elevated levels of glucagon-like peptide-1 (GLP-1), glucagon, insulin and leptin in A 1 +/+ mice ( Fig. 3a-d ). However, ageing only induced a small leptin increase in A 1 −/− mice.
No significant differences were observed in these hormone concentrations between the genotypes at a young age.
Insulin release and insulin content in isolated islets To investigate specifically whether A 1 receptors modulate insulin release upon glucose challenge, we used isolated islets. High glucose concentrations stimulated insulin release in batchtype incubations in both young and aged A 1 +/+ and A 1 −/− mice, but this response was attenuated during ageing ( Fig. 4a) . The relative insulin release response to glucose loading was significantly reduced in aged A 1 +/+ compared with young A 1 +/+ mice and also compared with age-matched A 1 −/− mice ( Fig. 4b ). This effect could not be explained by differences in total insulin content among the four groups investigated (Fig. 4c ). In addition, the islet morphology was similar among groups (ESM Fig. 1 ). Isolated and perfused islet arterioles To examine how the A 1 receptor influences the microvasculature, isolated and perfused pancreatic islet arterioles (Fig. 5a ) were used for vascular reactivity studies. In aged mice, glucose-induced dilation (Fig. 5c ). However, in young mice these differences were much less pronounced (Fig. 5b ). Simultaneous incubation with apocynin, to inhibit NADPH oxidase activity, attenuated ANG II-mediated contractions in A 1 +/+ mice (25±1% vs 12±3%), but had no effect on arterioles from A 1 −/− mice (13±3% vs 12±1%). With apocynin, the arteriolar responses were similar between A 1 +/+ and A 1 −/− mice (Fig. 5d) , suggesting that the difference between genotypes could be related to the regulation of NADPH oxidase function and oxidative stress. There was no difference with regard to the arteriolar diameters among groups (ESM Fig. 2 ).
NADPH oxidase-mediated superoxide production and Nox2 level To investigate further whether oxidative stress contributes to the pathogenesis of age-related metabolic disorders, O 2 − formation was measured in pancreas, liver and VAT. Ageing was associated with increased O 2 − generation in pancreas (Fig. 6a) and VAT (Fig. 6b) from A 1 +/+ mice. In A 1 −/− mice, this age-dependent change was much less and only occurred in pancreas. In agreement with this, the protein levels of Nox2 in both pancreas (Fig. 6c, e) and VAT (Fig. 6d, f) were significantly increased in A 1 +/+ mice during ageing while no significant changes were observed in A 1 −/− mice. Moreover, the Nox2 level in VAT in aged A 1 +/+ was significantly higher compared with that in A 1 −/− mice. No differences between genotypes were revealed in young mice. NADPH oxidase activity and Nox2 levels in liver were similar between genotypes and did not change with ageing.
Cytokines in plasma Considering the interaction between oxidative stress and inflammation, we measured systemic cytokine levels to investigate if abrogation of A 1 receptor signalling also influenced the inflammatory status. Advanced age was associated with elevated circulating TNF-α, IL-1β, IL-6, IL-12 and IL-10 levels in A 1 +/+ mice, but in aged A 1 −/− mice only IL-10 was elevated (Fig. 7a-e) . In agreement with this, the proinflammatory cytokines levels were significantly higher in aged A 1 +/+ mice compared with age-matched A 1 −/− mice. No differences of the cytokines investigated were observed between genotypes in young mice.
Populations of macrophages and T cells in VAT To further understand the potential role of A 1 signalling in regulating inflammation during ageing and metabolic disorder, flow cytometric analysis was performed on single-cell suspensions extracted from VAT (Fig. 8a ). There were no significant differences in total macrophage population in either young or aged mice between genotypes (Fig. 8b, d ), but the number of CD86 + macrophages was significantly higher in aged A 1 −/− mice compared with age-matched A 1 +/+ mice (Fig. 8c) . A 1 +/+ mice showed an age-related enhancement of total T cells and specifically of the CD4 + T cell population, this not being evident in A 1 −/− mice (Fig. 8e, f ). There were no differences regarding numbers of macrophages and T cells in the pancreas or liver.
Akt phosphorylation in VAT To examine if the difference in insulin sensitivity, oxidative stress and immune cell population was manifested in a downstream cellular event, we (Fig. 9a-d ). There were no differences in basal Akt and pAkt levels between genotypes (Fig. 9b, c) , but ageing was associated with significantly higher p-Akt/Akt ratio in aged A 1 +/+ compared with young A 1 +/+ mice (Fig. 9d) . Importantly, insulin-induced phosphorylation of Akt was markedly increased in A 1 −/− , but not significantly changed in agematched A 1 +/+ mice (Fig. 9d) . In another cohort, mice were treated with DPCPX 45 min prior to the insulin challenge. DPCPX alone did not change the expression and phosphorylation levels of Akt. However, acute inhibition of A 1 receptor signalling increased p-Akt and p-Akt/Akt ratio following insulin challenge in the A 1 +/+ mice, to the same level as in the A 1 −/− (Fig. 9e-h ).
Expression of adenosine receptors
To clarify if the different metabolic phenotypes during ageing and between A 1 +/+ and A 1 −/− mice were attributable to the possible differences of adenosine receptors expression, we used quantitative PCR to determine the expression of all four subtypes of adenosine receptors in pancreas (ESM Fig. 3a-d) , islets together with their arterioles (ESM Fig. 3e-h ) and in VAT (ESM Fig. 3i-l) . The A 1 receptor gene expression was undetectable in A 1 −/− mice.
In all tissues, no differences in A 2A , A 2B and A 3 receptor expression between genotypes were observed in either young or aged mice. The same adenosine receptor subtypes were also similarly expressed in young and aged mice of the same genotype. 
Discussion
Our major finding is that abrogation of A 1 signalling improves the metabolic profile during ageing. The underlying mechanisms are multifactorial: besides the known direct actions on lipolysis and lipogenesis [11, 12] , we found actions on peripheral insulin signalling, presumably via attenuation of NADPH oxidase function, as well as modulation of inflammatory pathways in VAT apparently being involved. Moreover, direct effects of A 1 signalling on the islet microvasculature, and insulin release, are also involved. We observed an age-dependent reduction in lean mass and an accumulation of VAT in wild-type but not in A 1 −/− mice. This is entirely compatible with previous studies showing that endogenous adenosine, through A 1 receptor signalling, reduces lipolysis and enhances lipogenesis [29] . We also found that advanced age was associated with elevated blood glucose levels, impaired glucose tolerance and insulin responses or signalling in A 1 +/+ but not in A 1 −/− mice. Pharmacological inhibition of the A 1 receptor improved glucose tolerance in aged wild-type mice, but had no effect in A 1 knockouts. Our data indicate that not only acute intervention of A 1 receptors will affect the metabolic function, but that A 1 receptors are also participating in the metabolic derangement in mice during ageing. Taken together, these findings demonstrate that A 1 receptor signalling influences both VAT and glucose regulation during ageing and emphasise the potential therapeutic value of targeting of A 1 receptors in type 2 diabetes. Adenosine is known to affect the endocrine pancreas per se [30] , and previous studies suggested that adenosine receptors can modulate insulin and glucagon secretion [13] . We found advanced age to be associated with an elevation of insulin, glucagon, GLP-1 and leptin in A 1 +/+ mice, but in aged A 1 −/− mice only leptin levels were increased. Thus, the beneficial effect of eliminating A 1 receptor signalling was extended to the hormone status. Increased leptin concentration or resistance were suggested as contributing to the inflammatory status in adipose tissue [31] and have been linked to ageassociated disorders including obesity, cardiovascular diseases, the metabolic syndrome and diabetes [32] [33] [34] [35] [36] . Elevated glucagon levels and insulin resistance are generally thought to contribute to the pathophysiology of hyperglycaemia in individuals with type 2 diabetes. Our islet studies demonstrated that the absence of A 1 receptors does not directly affect islet morphology or insulin content. However, ageing was associated with reduced glucose-stimulated insulin release in wild-type mice, but this age-dependent reduction was not observed in A 1 −/− mice. Islet blood flow is normally coupled to islet insulin release [37, 38] .
To provide a better possibility to study only the islet afferent arteriole, we used a recently developed technique with isolated and perfused single islets with attached arterioles [26] . Similar to that recently described for renal afferent arterioles [39] , islet arterioles from A 1 −/− mice displayed reduced contractility to ANG II. This was apparent during both normoand hyperglycaemic conditions, although much more profound during the latter. Since the baseline diameters of the islet arterioles were similar in all the groups, one may speculate that, at physiological ANG II concentrations, aged A 1 , has been demonstrated to reduce islet blood flow [40] . ANG II stimulates NADPH oxidase-mediated O 2 − formation, which contributes to its pronounced vasoactive properties. Interestingly, reduction of oxidative stress by the NADPH oxidase inhibitor apocynin attenuated ANG II-mediated contraction in A 1 +/+ mice, but had no effect on islet arterioles from A 1 −/− mice. This suggests an important role of the adenosine A 1 receptor in modulating O 2 − production. This notion has also been described in models of ANG II-induced hypertension in which blood pressure elevation and oxidative stress were markedly attenuated in A 1 genedeleted mice [39, 41] . Increasing evidence from experimental and clinical studies has demonstrated that oxidative stress and inflammation are key factors that contribute to the progression of metabolic disorders including type 2 diabetes [42, 43] . In the present study we show that ageing is associated with increased NADPH oxidase-derived O 2 − formation, together with higher Nox2 levels, in both pancreas and VAT from A 1 +/+ mice. This age-dependent elevation in O 2 − formation and oxidative stress was clearly attenuated, or even absent, in gene-deleted animals, which certainly may contribute to their better metabolic phenotype. Age-related VAT accumulation is associated with a chronic, low-grade inflammation and has been increasingly recognised as an independent risk factor of the pathogenesis of type 2 diabetes [44] [45] [46] . Almost all immune cell subsets are present in VAT. Their functions are still under discussion, although it is generally accepted that total T cell and macrophage populations are increased and contribute to the metainflammation evident in obesity. We did not discern differences in total macrophages among groups, but observed a significant enhancement of the CD86 + macrophage population in aged A 1 −/− mice, indicating elevated antigen presentation capacity. Interestingly, another recent study reported a lipolysis-related macrophage infiltration in adipose tissue without presenting pro-inflammatory characters [47] . As A 1 −/− mice have elevated lipolysis and remain lean, this enhancement of CD86 + macrophages may be due to a response to the continuous release of non-esterified fatty acids. As young mice have much lower lipolysis levels, no differences (e.g. in fat mass) were evident between genotypes at an early age. However, ageing resulted in a significant increase of total T cells and CD4 + T cells in VAT in A 1 +/+ mice, while this was not the case in and IL-12) were increased in aged A 1 +/+ but not in A 1 −/− mice.
These findings indicate that a sustained inflammation occurs during ageing and obesity, and may lead to subsequent metabolic disorders, as has been previously suggested [48, 49] . Moreover, accumulation of CD4 + T cells in VAT may be a key contributor to this systemic inflammation and can be modulated via A 1 receptor signalling. Further investigations on the immunomodulation effects of the A 1 receptor during ageing and the metabolic syndrome are needed and will provide additional insights in developing therapeutic strategies for type 2 diabetes. It seems likely that decreased VAT accumulation and inflammation may contribute to the better metabolic regulation in the stimulation. This insulin signalling pathway was markedly reduced in aged-matched wild-type mice and may contribute to their impaired glucose clearance function. Besides the A 1 receptor, also adenosine receptor A 2A and A 2B play a role in modulating glucose homeostasis and obesity [50, 51] . We did not reveal any significant differences regarding the A 2 and A 3 receptor expression among the groups, suggesting no compensatory changes following A 1 receptor deletion. Thus, we believe the improved metabolic phenotypes in the A 1 −/− mice in our study were due to the abrogation of A 1 signalling and our findings further suggest a pivotal role of the A 1 receptor in modulating especially the function of VAT, which may affect the metabolic homeostasis.
In conclusion, the present study demonstrates an important role of the adenosine A 1 receptor in modulating glucose and insulin homeostasis, as well as islet endocrine and arteriolar function, during ageing. Mechanistically, our findings suggest that abrogation of A 1 signalling may protect from agedependent oxidative stress and production of proinflammatory cytokines, and hence improve insulin release and signalling (Fig. 10) . Thus, abrogation of A 1 receptor signalling can both have acute effects and give long-term prevention of the development or progression of diabetes. Future studies in humans should be aimed at determining the therapeutic value of modulating A 1 signalling.
